Treatment patterns and concordance with NCCN guidelines by baseline disease risk. Distribution of treatment patterns in all patients with a LOS >3 days and known baseline risk status. Low-risk (n = 686) and high-risk (n = 322) patients were defined as WBC ≤10 G/L and WBC >10 G/L, respectively. Treatment regimens were classified based on current NCCN recommendations. ATRA + ATO was defined as the preferred regimen for low-risk APL (blue) with ATRA + ATO + anthracycline or GO constituting the preferred regimens for patients with high-risk APL (green). ATRA + anthracycline or GO can be used independent of disease risk in patients with contraindications to ATO and was included as a risk-agnostic, guideline-concordant treatment regimen among the respective NCCN guideline–concordant regimens in the low-risk (blue) and high-risk (green) patient populations.¹⁶  Other treatment regimens were classified as not NCCN-recommended (red). Overall, 86.1% of low-risk patients and 64.6% of high-risk patients with APL received guideline-concordant regimens for their risk status. Among patients with high-risk APL, 18.9% were treated with ATRA + ATO, a regimen that is NCCN concordant only for patients with low-risk APL. Data from the Vizient CDB used with permission of Vizient, Inc. All rights reserved.